-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Dexamethasone	B-I
on	O
Days	O
Alive	O
and	O
Ventilator	O
-	O
Free	O
in	O
Patients	B-P
With	I-P
Moderate	I-P
or	I-P
Severe	I-P
Acute	I-P
Respiratory	I-P
Distress	I-P
Syndrome	I-P
and	I-P
COVID	I-P
-	I-P
19	I-P
:	O
The	O
CoDEX	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
Multicenter	O
,	O
randomized	O
,	O
open	O
-	O
label	O
,	O
clinical	O
trial	O
conducted	O
in	O
41	O
intensive	O
care	O
units	O
(	O
ICUs	O
)	O
in	O
Brazil	O
.	O

Patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
moderate	I-P
to	I-P
severe	I-P
ARDS	I-P
,	I-P
according	I-P
to	I-P
the	I-P
Berlin	I-P
definition	I-P
,	O
were	O
enrolled	O
from	O
April	O
17	O
to	O
June	O
23	O
,	O
2020	O
.	O

Final	O
follow	O
-	O
up	O
was	O
completed	O
on	O
July	O
21	O
,	O
2020	O
.	O

The	O
trial	O
was	O
stopped	O
early	O
following	O
publication	O
of	O
a	O
related	O
study	O
before	O
reaching	O
the	O
planned	O
sample	O
size	O
of	O
350	O
patients	O
.	O

Twenty	B-I
mg	I-I
of	I-I
dexamethasone	I-I
intravenously	O
daily	O
for	O
5	O
days	O
,	O
10	B-I
mg	I-I
of	I-I
dexamethasone	I-I
daily	O
for	O
5	O
days	O
or	O
until	O
ICU	O
discharge	O
,	O
plus	O
standard	B-I
care	I-I
(	O
n	O
=151	O
)	O
or	O
standard	B-C
care	I-C
alone	I-C
(	O
n	O
=	O
148	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
ventilator	B-O
-	I-O
free	I-O
days	I-O
during	O
the	O
first	O
28	O
days	O
,	O
defined	O
as	O
being	B-O
alive	I-O
and	O
free	B-O
from	I-O
mechanical	I-O
ventilation	I-O
.	O

Secondary	O
outcomes	O
were	O
all	B-O
-	I-O
cause	I-O
mortality	I-O
at	O
28	O
days	O
,	O
clinical	B-O
status	I-O
of	I-O
patients	I-O
at	O
day	O
15	O
using	O
a	B-O
6	I-O
-	I-O
point	I-O
ordinal	I-O
scale	I-O
(	O
ranging	O
from	O
1	O
,	O
not	O
hospitalized	O
to	O
6	O
,	O
death	O
)	O
,	O
ICU	B-O
-	I-O
free	I-O
days	I-O
during	O
the	O
first	O
28	O
days	O
,	O
mechanical	B-O
ventilation	I-O
duration	I-O
at	O
28	O
days	O
,	O
and	O
Sequential	B-O
Organ	I-O
Failure	I-O
Assessment	I-O
(	I-O
SOFA	I-O
)	I-O
scores	I-O
(	O
range	O
,	O
0	O
-	O
24	O
,	O
with	O
higher	O
scores	O
indicating	O
greater	O
organ	O
dysfunction	O
)	O
at	O
48	O
hours	O
,	O
72	O
hours	O
,	O
and	O
7	O
days	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Hydrocortisone	B-I
on	O
Mortality	O
and	O
Organ	O
Support	O
in	O
Patients	B-P
With	I-P
Severe	I-P
COVID	I-P
-	I-P
19	I-P
:	O
The	O
REMAP	O
-	O
CAP	O
COVID	O
-	O
19	O
Corticosteroid	O
Domain	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
An	O
ongoing	O
adaptive	O
platform	O
trial	O
testing	O
multiple	O
interventions	O
within	O
multiple	O
therapeutic	O
domains	O
,	O
for	O
example	O
,	O
antiviral	O
agents	O
,	O
corticosteroids	O
,	O
or	O
immunoglobulin	O
.	O

Between	O
March	O
9	O
and	O
June	O
17	O
,	O
2020	O
,	O
614	B-P
adult	I-P
patients	I-P
with	I-P
suspected	I-P
or	I-P
confirmed	I-P
COVID	I-P
-	I-P
19	I-P
were	O
enrolled	O
and	O
randomized	O
within	O
at	O
least	O
1	O
domain	O
following	O
admission	O
to	O
an	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
for	O
respiratory	O
or	O
cardiovascular	O
organ	O
support	O
at	O
121	O
sites	O
in	O
8	O
countries	O
.	O

Of	O
these	O
,	O
403	O
were	O
randomized	O
to	O
open	O
-	O
label	O
interventions	O
within	O
the	O
corticosteroid	O
domain	O
.	O

The	O
domain	O
was	O
halted	O
after	O
results	O
from	O
another	O
trial	O
were	O
released	O
.	O

Follow	O
-	O
up	O
ended	O
August	O
12	O
,	O
2020	O
.	O

The	O
corticosteroid	O
domain	O
randomized	O
participants	O
to	O
a	B-I
fixed	I-I
7	I-I
-	I-I
day	I-I
course	I-I
of	I-I
intravenous	I-I
hydrocortisone	I-I
(	O
50	O
mg	O
or	O
100	O
mg	O
every	O
6	O
hours	O
)	O
(	O
n	O
=	O
143	O
)	O
,	O
a	B-I
shock	I-I
-	I-I
dependent	I-I
course	I-I
(	O
50	O
mg	O
every	O
6	O
hours	O
when	O
shock	O
was	O
clinically	O
evident	O
)	O
(	O
n	O
=	O
152	O
)	O
,	O
or	O
no	B-C
hydrocortisone	I-C
(	O
n	O
=	O
108	O
)	O
.	O

The	O
primary	O
end	O
point	O
was	O
organ	B-O
support	I-O
-	I-O
free	I-O
days	I-O
(	O
days	B-O
alive	I-O
and	O
free	B-O
of	I-O
ICU	I-O
-	I-O
based	I-O
respiratory	I-O
or	O
cardiovascular	B-O
support	I-O
)	O
within	O
21	O
days	O
,	O
where	O
patients	O
who	O
died	O
were	O
assigned	O
-	O
1	O
day	O
.	O

The	O
primary	O
analysis	O
was	O
a	O
bayesian	O
cumulative	O
logistic	O
model	O
that	O
included	O
all	O
patients	O
enrolled	O
with	O
severe	O
COVID	O
-	O
19	O
,	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
site	O
,	O
region	O
,	O
time	O
,	O
assignment	O
to	O
interventions	O
within	O
other	O
domains	O
,	O
and	O
domain	O
and	O
intervention	O
eligibility	O
.	O

Superiority	O
was	O
defined	O
as	O
the	O
posterior	O
probability	O
of	O
an	O
odds	O
ratio	O
greater	O
than	O
1	O
(	O
threshold	O
for	O
trial	O
conclusion	O
of	O
superiority	O
>	O
99	O
%	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
surgical	B-I
helmet	I-I
systems	I-I
for	O
protection	O
against	O
COVID	O
-	O
19	O
:	O
a	O
double	O
-	O
blinded	O
randomised	O
control	O
study	O
.	O

METHODS	O
:	O
Thirty	B-P
-	I-P
five	I-P
participants	I-P
were	O
enrolled	O
in	O
a	O
double	O
-	O
blinded	O
randomised	O
controlled	O
study	O
investigating	O
efficacy	O
of	O
the	B-I
Stryker	I-I
Flyte	I-I
Surgical	I-I
Helmet	I-I
(	O
Stryker	O
Corporation	O
,	O
Kalamazoo	O
,	O
MI	O
,	O
USA	O
)	O
as	O
protection	O
against	O
respiratory	O
droplets	O
.	O

Wearing	O
the	B-I
SSHS	I-I
in	O
a	O
fit	O
testing	O
hood	O
,	O
subjects	O
were	O
randomised	O
to	O
nebulised	B-I
saccharin	I-I
solution	I-I
or	O
placebo	B-C
.	O

Twenty	O
were	O
allocated	O
to	O
the	B-I
saccharin	I-I
group	O
with	O
15	O
to	O
placebo	B-C
.	O

Positive	O
sweet	O
taste	O
represented	O
a	O
failure	O
of	O
the	O
test	O
.	O

Taste	B-O
tests	I-O
were	O
performed	O
with	O
the	O
helmet	O
fan	O
turned	O
on	O
and	O
off	O
.	O

-DOCSTART-	O

Title	O
:	O
Azithromycin	B-I
in	O
addition	O
to	O
standard	B-I
of	I-I
care	I-I
versus	O
standard	B-C
of	I-C
care	I-C
alone	I-C
in	O
the	O
treatment	O
of	O
patients	B-P
admitted	I-P
to	I-P
the	I-P
hospital	I-P
with	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
in	I-P
Brazil	I-P
(	O
COALITION	O
II	O
)	O
:	O
a	O
randomised	O
clinical	O
trial	O
.	O

METHODS	O
:	O
We	O
did	O
an	O
open	O
-	O
label	O
,	O
randomised	O
clinical	O
trial	O
at	O
57	O
centres	O
in	O
Brazil	O
.	O

We	O
enrolled	O
patients	B-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
suspected	I-P
or	I-P
confirmed	I-P
COVID	I-P
-	I-P
19	I-P
and	O
at	O
least	O
one	O
additional	O
severity	O
criteria	O
as	O
follows	O
:	O
use	O
of	O
oxygen	O
supplementation	O
of	O
more	O
than	O
4	O
L	O
/	O
min	O
flow	O
;	O
use	O
of	O
high	O
-	O
flow	O
nasal	O
cannula	O
;	O
use	O
of	O
non	O
-	O
invasive	O
mechanical	O
ventilation	O
;	O
or	O
use	O
of	O
invasive	O
mechanical	O
ventilation	O
.	O

Patients	O
were	O
randomly	O
assigned	O
(	O
1	O
:	O
1	O
)	O
to	O
azithromycin	B-I
(	O
500	O
mg	O
via	O
oral	O
,	O
nasogastric	O
,	O
or	O
intravenous	O
administration	O
once	O
daily	O
for	O
10	O
days	O
)	O
plus	O
standard	B-I
of	I-I
care	I-I
or	O
to	O
standard	B-C
of	I-C
care	I-C
without	O
macrolides	B-C
.	O

All	O
patients	O
received	O
hydroxychloroquine	B-I
(	O
400	O
mg	O
twice	O
daily	O
for	O
10	O
days	O
)	O
because	O
that	O
was	O
part	O
of	O
standard	O
of	O
care	O
treatment	O
in	O
Brazil	O
for	O
patients	O
with	O
severe	O
COVID	O
-	O
19	O
.	O

The	O
primary	O
outcome	O
,	O
assessed	O
by	O
an	O
independent	O
adjudication	O
committee	O
masked	O
to	O
treatment	O
allocation	O
,	O
was	O
clinical	B-O
status	I-O
at	O
day	O
15	O
after	O
randomisation	O
,	O
assessed	O
by	O
a	B-O
six	I-O
-	I-O
point	I-O
ordinal	I-O
scale	I-O
,	O
with	O
levels	O
ranging	O
from	O
1	O
to	O
6	O
and	O
higher	O
scores	O
indicating	O
a	O
worse	O
condition	O
(	O
with	O
odds	O
ratio	O
[	O
OR	O
]	O
greater	O
than	O
100	O
favouring	O
the	O
control	O
group	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
assessed	O
in	O
all	O
patients	O
in	O
the	O
intention	O
-	O
to	O
-	O
treat	O
(	O
ITT	O
)	O
population	O
who	O
had	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
2	O
infection	O
confirmed	O
by	O
molecular	O
or	O
serological	O
testing	O
before	O
randomisation	O
(	O
ie	O
,	O
modified	O
ITT	O
[	O
mITT	O
]	O
population	O
)	O
.	O

Safety	O
was	O
assessed	O
in	O
all	O
patients	O
according	O
to	O
which	O
treatment	O
they	O
received	O
,	O
regardless	O
of	O
original	O
group	O
assignment	O
.	O

This	O
trial	O
was	O
registered	O
at	O
ClinicalTrials	O
.	O
gov	O
,	O
NCT04321278	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Recombinant	B-I
Human	I-I
Granulocyte	I-I
Colony	I-I
-	O
Stimulating	O
Factor	O
for	O
Patients	B-P
With	I-P
Coronavirus	I-P
Disease	I-P
2019	I-P
(	I-P
COVID	I-P
-	I-P
19	I-P
)	I-P
and	I-P
Lymphopenia	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
Between	O
February	O
18	O
and	O
April	O
10	O
,	O
2020	O
,	O
we	O
conducted	O
an	O
open	O
-	O
label	O
,	O
multicenter	O
,	O
randomized	O
clinical	O
trial	O
at	O
3	O
participating	O
centers	O
in	O
China	O
.	O

The	O
main	O
eligibility	O
criteria	O
were	O
pneumonia	O
,	O
a	O
blood	O
lymphocyte	O
cell	O
count	O
of	O
800	O
per	O
?L	O
(	O
to	O
convert	O
to	O
109	O
/	O
L	O
,	O
multiply	O
by	O
0	O
.	O
001	O
)	O
or	O
lower	O
,	O
and	O
no	O
comorbidities	O
.	O

Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
2	O
infection	O
was	O
confirmed	O
with	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
testing	O
.	O

Usual	B-C
care	I-C
alone	I-C
,	O
or	O
usual	B-I
care	I-I
plus	O
3	B-I
doses	I-I
of	I-I
recombinant	I-I
human	I-I
granulocyte	I-I
colony	I-I
-	I-I
stimulating	I-I
factor	I-I
(	I-I
rhG	I-I
-	I-I
CSF	I-I
,	O
5	O
?g	O
/	O
kg	O
,	O
subcutaneously	O
at	O
days	O
0	O
-	O
2	O
)	O
.	O

The	O
primary	O
end	O
point	O
was	O
the	B-O
time	I-O
from	I-O
randomization	I-O
to	I-O
improvement	I-O
of	O
at	O
least	O
1	O
point	O
on	O
a	B-O
7	I-O
-	I-O
category	I-O
disease	I-O
severity	I-O
score	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Intravenous	B-I
methylprednisolone	I-I
pulse	I-I
as	O
a	O
treatment	O
for	O
hospitalised	B-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
:	O
results	O
from	O
a	O
randomised	O
controlled	O
clinical	O
trial	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
single	O
-	O
blind	O
,	O
randomised	O
controlled	O
clinical	O
trial	O
involving	O
severe	B-P
hospitalised	I-P
patients	I-P
with	I-P
confirmed	I-P
COVID	I-P
-	I-P
19	I-P
at	I-P
the	I-P
early	I-P
pulmonary	I-P
phase	I-P
of	I-P
the	I-P
illness	I-P
in	I-P
Iran	I-P
.	O

The	O
patients	O
were	O
randomly	O
allocated	O
in	O
a	O
1	O
:	O
1	O
ratio	O
by	O
the	O
block	O
randomisation	O
method	O
to	O
receive	O
standard	B-I
care	I-I
with	O
methylprednisolone	B-I
pulse	I-I
(	O
intravenous	O
injection	O
,	O
250	O
mgday	O
-	O
1	O
for	O
3	O
days	O
)	O
or	O
standard	B-C
care	I-C
alone	I-C
.	O

The	O
study	O
end	O
-	O
point	O
was	O
the	B-O
time	I-O
of	I-O
clinical	I-O
improvement	I-O
or	O
death	B-O
,	O
whichever	O
came	O
first	O
.	O

Primary	O
and	O
safety	O
analysis	O
was	O
done	O
in	O
the	O
intention	O
-	O
to	O
-	O
treat	O
(	O
ITT	O
)	O
population	O
.	O

-DOCSTART-	O

Title	O
:	O
Double	O
-	O
blind	O
,	O
Randomized	O
,	O
Placebo	O
-	O
controlled	O
Trial	O
With	O
N	B-I
-	I-I
acetylcysteine	I-I
for	O
Treatment	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Caused	O
by	O
Coronavirus	O
Disease	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
single	O
-	O
center	O
trial	O
conducted	O
at	O
the	O
Emergency	O
Department	O
of	O
Hospital	O
das	O
Clnicas	O
,	O
So	O
Paulo	O
,	O
Brazil	O
,	O
to	O
determine	O
whether	O
NAC	B-I
in	O
high	O
doses	O
can	O
avoid	O
respiratory	O
failure	O
in	O
patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
.	O

We	O
enrolled	O
135	B-P
patients	I-P
with	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
(	I-P
confirmed	I-P
or	I-P
suspected	I-P
)	I-P
,	I-P
with	I-P
an	I-P
oxyhemoglobin	I-P
saturation	I-P
<	I-P
94	I-P
%	I-P
or	I-P
respiratory	I-P
rate	I-P
>	I-P
24	I-P
breaths	I-P
/	I-P
minute	I-P
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
NAC	B-I
21	O
g	O
(	O
~	O
300	O
mg	O
/	O
kg	O
)	O
for	O
20	O
hours	O
or	O
dextrose	B-C
5	O
%	O
.	O

The	O
primary	O
endpoint	O
was	O
the	B-O
need	I-O
for	I-O
mechanical	I-O
ventilation	I-O
.	O

Secondary	O
endpoints	O
were	O
time	B-O
of	I-O
mechanical	I-O
ventilation	I-O
,	O
admission	B-O
to	I-O
the	I-O
intensive	I-O
care	I-O
unit	I-O
(	I-O
ICU	I-O
)	I-O
,	O
time	B-O
in	I-O
ICU	I-O
,	O
and	O
mortality	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Hydroxychloroquine	B-I
in	O
Hospitalized	B-P
Patients	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
.	O

METHODS	O
:	O
In	O
this	O
randomized	O
,	O
controlled	O
,	O
open	O
-	O
label	O
platform	O
trial	O
comparing	O
a	O
range	O
of	O
possible	O
treatments	O
with	O
usual	O
care	O
in	O
patients	B-P
hospitalized	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
,	O
we	O
randomly	O
assigned	O
1561	O
patients	O
to	O
receive	O
hydroxychloroquine	B-I
and	O
3155	O
to	O
receive	O
usual	B-C
care	I-C
.	O

The	O
primary	O
outcome	O
was	O
28	B-O
-	I-O
day	I-O
mortality	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Lopinavir	B-I
-	O
ritonavir	B-I
in	O
patients	B-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
(	O
RECOVERY	O
)	O
:	O
a	O
randomised	O
,	O
controlled	O
,	O
open	O
-	O
label	O
,	O
platform	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
randomised	O
,	O
controlled	O
,	O
open	O
-	O
label	O
,	O
platform	O
trial	O
,	O
a	O
range	O
of	O
possible	O
treatments	O
was	O
compared	O
with	O
usual	B-C
care	I-C
in	O
patients	B-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
.	O

The	O
trial	O
is	O
underway	O
at	O
176	O
hospitals	O
in	O
the	O
UK	O
.	O

Eligible	O
and	O
consenting	O
patients	O
were	O
randomly	O
allocated	O
to	O
either	O
usual	B-C
standard	I-C
of	I-C
care	I-C
alone	I-C
or	O
usual	B-I
standard	I-I
of	I-I
care	I-I
plus	O
lopinavir	B-I
-	O
ritonavir	B-I
(	O
400	O
mg	O
and	O
100	O
mg	O
,	O
respectively	O
)	O
by	O
mouth	O
for	O
10	O
days	O
or	O
until	O
discharge	O
(	O
or	O
one	O
of	O
the	O
other	O
RECOVERY	O
treatment	O
groups	O
:	O
hydroxychloroquine	B-I
,	O
dexamethasone	B-I
,	O
or	O
azithromycin	B-I
)	O
using	O
web	O
-	O
based	O
simple	O
(	O
unstratified	O
)	O
randomisation	O
with	O
allocation	O
concealment	O
.	O

Randomisation	O
to	O
usual	B-C
care	I-C
was	O
twice	O
that	O
of	O
any	O
of	O
the	O
active	O
treatment	O
groups	O
(	O
eg	O
,	O
2	O
:	O
1	O
in	O
favour	O
of	O
usual	B-C
care	I-C
if	O
the	O
patient	O
was	O
eligible	O
for	O
only	O
one	O
active	O
group	O
,	O
2:1:1	O
if	O
the	O
patient	O
was	O
eligible	O
for	O
two	O
active	O
groups	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
28	B-O
-	I-O
day	I-O
all	I-O
-	I-O
cause	I-O
mortality	I-O
.	O

Analyses	O
were	O
done	O
on	O
an	O
intention	O
-	O
to	O
-	O
treat	O
basis	O
in	O
all	O
randomly	O
assigned	O
participants	O
.	O

The	O
trial	O
is	O
registered	O
with	O
ISRCTN	O
,	O
50189673	O
,	O
and	O
ClinicalTrials	O
.	O
gov	O
,	O
NCT04381936	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
value	O
of	O
high	B-I
-	I-I
flow	I-I
nasal	I-I
cannula	I-I
oxygen	I-I
therapy	I-I
in	O
treating	O
novel	O
coronavirus	O
pneumonia	O
.	O

METHODS	O
:	O
The	O
clinical	O
data	O
of	O
22	B-P
patients	I-P
with	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
were	O
collected	O
.	O

The	B-O
heart	I-O
rate	I-O
(	I-O
HR	I-O
)	I-O
,	O
respiratory	B-O
rate	I-O
(	I-O
RR	I-O
)	I-O
and	O
oxygenation	B-O
index	I-O
(	O
PO2	B-O
/	O
FiO2	B-O
)	O
at	O
0	O
,	O
6	O
,	O
24	O
and	O
72	O
hours	O
after	O
treatment	O
were	O
compared	O
between	O
the	B-I
HFNC	I-I
oxygen	I-I
therapy	I-I
group	O
and	O
the	B-C
conventional	I-C
oxygen	I-C
therapy	I-C
(	I-C
COT	I-C
)	I-C
group	O
.	O

In	O
addition	O
,	O
the	B-O
white	I-O
blood	I-O
cell	I-O
(	I-O
WBC	I-O
)	I-O
count	I-O
,	O
lymphocyte	B-O
(	I-O
L	I-O
)	I-O
count	I-O
,	O
C	B-O
-	I-O
reactive	I-O
protein	I-O
(	I-O
CRP	I-O
)	I-O
and	O
procalcitonin	B-O
(	I-O
PCT	I-O
)	I-O
were	O
compared	O
before	O
and	O
at	O
72	O
hours	O
after	O
oxygen	O
therapy	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Tocilizumab	B-I
vs	O
Usual	B-C
Care	I-C
in	O
Adults	B-P
Hospitalized	I-P
With	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
Moderate	I-P
or	I-P
Severe	I-P
Pneumonia	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
This	O
cohort	O
-	O
embedded	O
,	O
investigator	O
-	O
initiated	O
,	O
multicenter	O
,	O
open	O
-	O
label	O
,	O
bayesian	O
randomized	O
clinical	O
trial	O
investigating	O
patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
moderate	I-P
or	I-P
severe	I-P
pneumonia	I-P
requiring	I-P
at	I-P
least	I-P
3	I-P
L	I-P
/	I-P
min	I-P
of	I-P
oxygen	I-P
but	I-P
without	I-P
ventilation	I-P
or	I-P
admission	I-P
to	I-P
the	I-P
intensive	I-P
care	I-P
unit	I-P
was	I-P
conducted	I-P
between	I-P
March	I-P
31	I-P
,	I-P
2020	I-P
,	I-P
to	I-P
April	I-P
18	I-P
,	I-P
2020	I-P
,	I-P
with	I-P
follow	I-P
-	I-P
up	I-P
through	I-P
28	I-P
days	I-P
.	O

Patients	O
were	O
recruited	O
from	O
9	O
university	O
hospitals	O
in	O
France	O
.	O

Analyses	O
were	O
performed	O
on	O
an	O
intention	O
-	O
to	O
-	O
treat	O
basis	O
with	O
no	O
correction	O
for	O
multiplicity	O
for	O
secondary	O
outcomes	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
TCZ	B-I
,	O
8	O
mg	O
/	O
kg	O
,	O
intravenously	O
plus	O
usual	B-I
care	I-I
on	O
day	O
1	O
and	O
on	O
day	O
3	O
if	O
clinically	O
indicated	O
(	O
TCZ	B-I
group	O
)	O
or	O
to	O
receive	O
usual	B-C
care	I-C
alone	I-C
(	O
UC	B-C
group	O
)	O
.	O

Usual	B-I
care	I-I
included	O
antibiotic	B-I
agents	I-I
,	O
antiviral	B-I
agents	I-I
,	O
corticosteroids	B-I
,	O
vasopressor	B-I
support	I-I
,	O
and	O
anticoagulants	B-I
.	O

Primary	O
outcomes	O
were	O
scores	O
higher	O
than	O
5	O
on	O
the	B-O
World	I-O
Health	I-O
Organization	I-O
10	I-O
-	I-O
point	I-O
Clinical	I-O
Progression	I-O
Scale	I-O
(	I-O
WHO	I-O
-	I-O
CPS	I-O
)	I-O
on	O
day	O
4	O
and	O
survival	B-O
without	I-O
need	I-O
of	I-O
ventilation	I-O
(	O
including	O
noninvasive	B-O
ventilation	I-O
)	O
at	O
day	O
14	O
.	O

Secondary	O
outcomes	O
were	O
clinical	B-O
status	I-O
assessed	O
with	O
the	B-O
WHO	I-O
-	I-O
CPS	I-O
scores	I-O
at	O
day	O
7	O
and	O
day	O
14	O
,	O
overall	B-O
survival	I-O
,	O
time	B-O
to	I-O
discharge	I-O
,	O
time	B-O
to	I-O
oxygen	I-O
supply	I-O
independency	I-O
,	O
biological	B-O
factors	I-O
such	O
as	O
C	B-O
-	I-O
reactive	I-O
protein	I-O
level	I-O
,	O
and	O
adverse	B-O
events	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
Tocilizumab	B-I
in	O
Patients	B-P
Hospitalized	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
.	O

METHODS	O
:	O
We	O
performed	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
involving	O
patients	B-P
with	I-P
confirmed	I-P
severe	I-P
acute	I-P
respiratory	I-P
syndrome	I-P
coronavirus	I-P
2	I-P
(	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
)	I-P
infection	I-P
,	I-P
hyperinflammatory	I-P
states	I-P
,	I-P
and	I-P
at	I-P
least	I-P
two	I-P
of	I-P
the	I-P
following	I-P
signs	I-P
:	I-P
fever	I-P
(	I-P
body	I-P
temperature	I-P
>	I-P
38	I-P
	I-P
C	I-P
)	I-P
,	I-P
pulmonary	I-P
infiltrates	I-P
,	I-P
or	I-P
the	I-P
need	I-P
for	I-P
supplemental	I-P
oxygen	I-P
in	I-P
order	I-P
to	I-P
maintain	I-P
an	I-P
oxygen	I-P
saturation	I-P
greater	I-P
than	I-P
92	I-P
%	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
in	O
a	O
2	O
:	O
1	O
ratio	O
to	O
receive	O
standard	B-I
care	I-I
plus	O
a	B-I
single	I-I
dose	I-I
of	I-I
either	I-I
tocilizumab	I-I
(	O
8	O
mg	O
per	O
kilogram	O
of	O
body	O
weight	O
)	O
or	O
placebo	B-C
.	O

The	O
primary	O
outcome	O
was	O
intubation	B-O
or	O
death	B-O
,	O
assessed	O
in	O
a	O
time	O
-	O
to	O
-	O
event	O
analysis	O
.	O

The	O
secondary	O
efficacy	O
outcomes	O
were	O
clinical	B-O
worsening	I-O
and	O
discontinuation	B-O
of	I-O
supplemental	I-O
oxygen	I-O
among	O
patients	O
who	O
had	O
been	O
receiving	O
it	O
at	O
baseline	O
,	O
both	O
assessed	O
in	O
time	O
-	O
to	O
-	O
event	O
analyses	O
.	O

-DOCSTART-	O

Title	O
:	O
Convalescent	B-I
plasma	I-I
in	O
the	O
management	O
of	O
moderate	O
covid	O
-	O
19	O
in	O
adults	B-P
in	I-P
India	I-P
:	O
open	O
label	O
phase	O
II	O
multicentre	O
randomised	O
controlled	O
trial	O
(	O
PLACID	O
Trial	O
)	O
.	O

METHODS	O
:	O
Open	O
label	O
,	O
parallel	O
arm	O
,	O
phase	O
II	O
,	O
multicentre	O
,	O
randomised	O
controlled	O
trial	O
.	O

39	O
public	O
and	O
private	O
hospitals	O
across	O
India	O
.	O

464	B-P
adults	I-P
(	I-P
?18	I-P
years	I-P
)	I-P
admitted	I-P
to	I-P
hospital	I-P
(	I-P
screened	I-P
22	I-P
April	I-P
to	I-P
14	I-P
July	I-P
2020	I-P
)	I-P
with	I-P
confirmed	I-P
moderate	I-P
covid	I-P
-	I-P
19	I-P
(	I-P
partial	I-P
pressure	I-P
of	I-P
oxygen	I-P
in	I-P
arterial	I-P
blood	I-P
/	I-P
fraction	I-P
of	I-P
inspired	I-P
oxygen	I-P
(	I-P
PaO2	I-P
/	I-P
FiO2	I-P
)	I-P
ratio	I-P
between	I-P
200	I-P
mm	I-P
Hg	I-P
and	I-P
300	I-P
mm	I-P
Hg	I-P
or	I-P
a	I-P
respiratory	I-P
rate	I-P
of	I-P
more	I-P
than	I-P
24	I-P
/	I-P
min	I-P
with	I-P
oxygen	I-P
saturation	I-P
93	I-P
%	I-P
or	I-P
less	I-P
on	I-P
room	I-P
air	I-P
)	I-P
:	O
235	O
were	O
assigned	O
to	O
convalescent	B-I
plasma	I-I
with	B-I
best	I-I
standard	I-I
of	I-I
care	I-I
(	O
intervention	O
arm	O
)	O
and	O
229	O
to	O
best	B-C
standard	I-C
of	I-C
care	I-C
only	I-C
(	O
control	O
arm	O
)	O
.	O

Participants	O
in	O
the	O
intervention	O
arm	O
received	O
two	B-I
doses	I-I
of	I-I
200	I-I
mL	I-I
convalescent	I-I
plasma	I-I
,	O
transfused	O
24	O
hours	O
apart	O
.	O

The	O
presence	O
and	O
levels	O
of	O
neutralising	O
antibodies	O
were	O
not	O
measured	O
a	O
priori	O
;	O
stored	O
samples	O
were	O
assayed	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

Composite	B-O
of	I-O
progression	I-O
to	I-O
severe	I-O
disease	I-O
(	O
PaO2	B-O
/	O
FiO2	B-O
<	O
100	O
mm	O
Hg	O
)	O
or	O
all	B-O
cause	I-O
mortality	I-O
at	O
28	O
days	O
post	O
-	O
enrolment	O
.	O

-DOCSTART-	O

Title	O
:	O
Randomized	O
,	O
Placebo	O
-	O
controlled	O
Trial	O
of	O
Inhaled	B-I
Treprostinil	I-I
for	O
Patients	B-P
at	I-P
Risk	I-P
for	I-P
Acute	I-P
Respiratory	I-P
Distress	I-P
Syndrome	I-P
.	O

METHODS	O
:	O
We	O
performed	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
single	O
-	O
center	O
randomized	O
pilot	O
trial	O
at	O
a	O
quaternary	O
care	O
academic	O
medical	O
center	O
.	O

Patients	B-P
with	I-P
acute	I-P
hypoxemia	I-P
due	I-P
to	I-P
pneumonia	I-P
or	I-P
signs	I-P
of	I-P
low	I-P
-	I-P
pressure	I-P
pulmonary	I-P
edema	I-P
with	I-P
a	I-P
unilateral	I-P
or	I-P
bilateral	I-P
infiltrate	I-P
on	I-P
chest	I-P
imaging	I-P
and	I-P
a	I-P
4	I-P
L	I-P
/	I-P
min	I-P
supplemental	I-P
oxygen	I-P
requirement	I-P
not	I-P
requiring	I-P
positive	I-P
pressure	I-P
ventilation	I-P
were	O
evaluated	O
.	O

Randomized	O
patients	O
received	O
study	O
drug	O
or	O
placebo	B-C
(	O
2	O
:	O
1	O
ratio	O
)	O
.	O

Treatment	O
was	O
initiated	O
at	O
6	O
breaths	O
every	O
4	O
hours	O
and	O
titrated	O
up	O
to	O
12	O
breaths	O
.	O

Subjects	O
were	O
maintained	O
on	O
treatment	O
for	O
7	O
days	O
and	O
then	O
tapered	O
off	O
over	O
a	O
period	O
of	O
4	O
days	O
.	O

Study	O
drug	O
was	O
stopped	O
if	O
positive	B-O
pressure	I-O
ventilation	I-O
was	O
required	O
(	O
invasive	O
or	O
noninvasive	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Clinical	O
Outcomes	O
and	O
Plasma	O
Concentrations	O
of	O
Baloxavir	B-I
Marboxil	I-I
and	O
Favipiravir	B-I
in	O
COVID	B-P
-	I-P
19	I-P
Patients	I-P
:	O
An	O
Exploratory	O
Randomized	O
,	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
Favipiravir	B-I
and	O
baloxavir	B-I
acid	I-I
were	O
evaluated	O
for	O
their	O
antiviral	O
activity	O
against	O
SARS	O
-	O
CoV	O
-	O
2	O
in	O
vitro	O
before	O
the	O
trial	O
initiation	O
.	O

We	O
conducted	O
an	O
exploratory	O
trial	O
with	O
3	O
arms	O
involving	O
hospitalized	B-P
adult	I-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
.	O

Patients	O
were	O
randomized	O
assigned	O
in	O
a	O
1:1:1	O
ratio	O
into	O
baloxavir	B-I
marboxil	I-I
group	O
,	O
favipiravir	B-I
group	O
,	O
and	O
control	O
group	O
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
percentage	I-O
of	I-O
subjects	I-O
with	I-O
viral	I-O
negative	I-O
by	O
Day	O
14	O
and	O
the	B-O
time	I-O
from	I-O
randomization	I-O
to	I-O
clinical	I-O
improvement	I-O
.	O

Virus	B-O
load	I-O
reduction	I-O
,	O
blood	B-O
drug	I-O
concentration	I-O
and	O
clinical	B-O
presentation	I-O
were	O
also	O
observed	O
.	O

The	O
trial	O
was	O
registered	O
with	O
Chinese	O
Clinical	O
Trial	O
Registry	O
(	O
ChiCTR	O
2000029544	O
)	O
.	O

